Industry Veteran Keith Warner New COO at Attune Medical

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.


Keith Warner, COO, Attune Medical
Keith Warner, COO, Attune Medical

Attune Medical (formerly Advanced Cooling Therapy), an emerging medical device firm, announced today that they have hired industry veteran Keith Warner as their Chief Operating Officer.

Mr. Warner comes to Attune with over three decades of experience building high value companies.  Most recently as a consultant to life science investment firms, Mr. Warner has been instrumental in assessing new technologies and building early stage companies toward successful M&A transactions.  Mr. Warner served in leadership roles at organizations including Wafergen BioSystems, Novartis/Chiron and Biodesix.  He also held numerous positions of increasing responsibility in manufacturing, sales and marketing and management at Abbott Diagnostics.  Mr. Warner received his undergraduate degree in microbiology from Kansas State University and his M.B.A. from Pepperdine University.

Erik Kulstad, Founder and CEO:  “The addition of Keith to the team will support our aggressive growth trajectory as the EnsoETM continues to gain global adoption.  His significant commercial and operational experience, reputation of excellence, and industry insight will help Attune continue to innovate in patient temperature management.”

Mr. Warner replied, “I look forward to accelerating the progress made by Dr. Kulstad and his team toward maximizing the clinical impact of esophageal-based temperature management.  Recent progress toward closing additional financing and attracting key contributors to the Attune team will position the company as a leader in patient temperature management.”

Attune Medical’s proprietary technology allows providers to safely and efficiently control core patient temperature, whether warming or cooling, through the esophagus when clinically indicated. Attune Medical’s primary device, the EnsoETM (formerly Esophageal Cooling Device or ECD), is designed to modulate and control patient temperature through a single use, fully-enclosed system that is inserted into the esophagus.  Two lumens attach to an external heat exchange unit while a third, independent, lumen simultaneously allows gastric decompression and drainage.  The EnsoETM can be rapidly placed by most trained healthcare professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or intensive care unit.  No other products on the market are approved to use the esophageal environment for whole-body temperature modulation.

Attune Medical (as Advanced Cooling Therapy) received US FDA de novo clearance for the EnsoETM (Esophageal Cooling Device or ECD) in 2015 for use with the Medi-Therm III by Stryker®.  It received FDA 510(k) clearance in 2016 for use with the Blanketrol® II and III Hyper-Hypothermia systems made by Cincinnati Sub-Zero, a Gentherm Company, and FDA 510(k) clearance for use with the Altrix System by Stryker® in 2017. It received its CE Mark in Europe in 2014, with an expanded indication for use up to 120 hours in 2016 and a CE Mark for use with the Altrix System by Stryker® in 2017.  It is also licensed for sale in Canada and Australia.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.